Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
Fibrinolysis in acute myocardial infarction activates blood coagulation and may favor reocclusion or ischemic complications. The aim of the GUSTO V Italian Hematologic Substudy was to compare the effects of full-dose reteplase on coagulation activation markers with those of half-dose reteplase combined with full-dose abciximab, a platelet glycoprotein IIb/IIIa receptor antagonist, during the early phase after acute myocardial infarction.
Merlini
Piera Angelica
PA
Division of Cardiology, Ospedale Niguarda, Milan, Italy. ARDIS001@planet.it
Repetto
Alessandra
A
Andreoli
Anna Maria
AM
Ricci
Silvio
S
Lombardi
Alessandro
A
Finardi
Angelo
A
Dipasquale
Giuseppe
G
Lamponi
Monica
M
Mannucci
Pier Mannuccio
PM
Ardissino
Diego
D
D000077284:Abciximab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007124:Immunoenzyme Techniques; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D015539:Platelet Activation / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011516:Prothrombin / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013917:Thrombin / Q000096:biosynthesis*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D011516:Prothrombin; D006493:Heparin; C087896:reteplase; D013917:Thrombin; D010959:Tissue Plasminogen Activator; D000077284:Abciximab